Each mL contains Hyoscine-N-Butylbromide 20 mg.
Pharmacology: Hyoscine Butylbromide is a quaternary ammonium agent. Hyoscine butylbromide does not readily pass the blood-brain barrier. It's a competitive antagonist of the actions of acetylcholine and other muscarinic agonists. The receptors affected are those of peripheral structures that are either stimulated or inhibited by muscarine, i.e. exocrine glands, smooth and cardiac muscles.
Pharmacokinetics: Hyoscine is readily absorbed from the gastrointestinal tract following oral doses of the hydrobromide. It is almost entirely metabolized, probably in the liver; only a small proportion of an oral dose has been reported to be excreted unchanged in the urine. It crosses the blood-brain barrier and has been stated to cross the placenta.
Hyoscine-N-Butylbromide is an antispasmodic agent, indicated in the urogenital tract, digestive tract (colics, ulcers and severe gastritis). It can also be used to reduce the spasms in diagnostic procedures such as gastro-duodenal endoscopy. Also used for cholinomimetic poisoning; e.g. cholinesterase inhibitor insecticides, reversal of muscarinic symptoms in patients with mushroom poisoning.
Administer by intramuscular or intravenous injection.
Adults: 20 mg.
Children under 15 years: 15 mg.
Administration can be repeated after 30 minutes when necessary. Hyoscine-N-Butylbromide injection may be diluted with Dextrose 5% or with sodium chloride 0.9% Solution for infusion.
This product contains sodium metabisulfite which can cause hypersensitivity reactions including broncho spasm and anaphylaxis.
Patients who experience drowsiness should not drive or operate machinery. Alcohol should be avoided. Caution in elderly patients, patients with seizure disorder and in patients with impaired metabolic, liver, or kidney function.
It has been stated that in elderly patients and patients with impaired metabolic, liver or kidney function, adverse central nervous system effects such as disorientation, delirium, or somnolence have been likely to occur.
Caution in breastfeeding mothers (given parenterally).
Caution in breastfeeding mothers (given parenterally).
Hyoscine produces central depression at therapeutic doses and symptoms include drowsiness and fatigue.
Dryness of the mouth, with difficulty in swallowing, thirst, dilation of the pupils with loss of accommodation and photophobia, increased intra-ocular pressure, flushing and dryness of the skin, bradycardia followed by tachycardia, with palpitations and arrhythmias, urinary urgency with the inability to do so, as well as reduction in the tone and motility of the gastro-intestinal tract, leading to constipation. Occasionally vomiting, giddiness and staggering may occur. Retrosternal pain may occur due to increased gastric reflux.
The sedative effect of hyoscine may be enhanced by alcohol or other CNS depressants.
Store at temperatures not exceeding 30°C.
Protect from light.
A03BB01 - butylscopolamine ; Belongs to the class of belladonna alkaloids, semisynthetic, quaternary ammonium compounds. Used in the treatment of functional gastrointestinal disorders.
Hyosan soln for inj 20 mg/mL
10 × 1's (P85/ampoule)
Sign Out
